Meeting Banner
Abstract #2767

In vivo imaging of tumor physiological, metabolic and redox changes in response to the anti-angiogenic agent sunitinib: Longitudinal assessment to indentify the transient vascular re-normalization.

Shingo Matsumoto 1 , Keita Saito 1 , Jeeva P Munasinghe 2 , Herman D Morris 2 , Martin J Lizak 2 , Shun Kishimoto 1 , Nallathamby Devasahayam 1 , Sankaran Suburamanian 1 , James B Mitchell 1 , and Murali C Krishna 1

1 National Cancer Institute, NIH, Bethesda, MD, United States, 2 National Institute of Neurological Disorder and Stroke, Bethesda, MD, United States

Anti-angiogenic therapies of solid tumors frequently proceed in two steps: transient normalization of structurally and functionally aberrant tumor blood vessels with increased blood perfusion, followed by pruning the tumor blood vessels and resultant cessation of nutrients and oxygen delivery required for tumor growth. We investigated if imaging of redox status governed by redox sensitive metabolic couples in tumors can serve as non-invasive surrogate makers for the vascular normalization window. Multimodal imaging approach of tumor physiological, metabolic and redox changes is useful to distinguish different stages in the course of anti-angiogenic treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here